1
|
Yuki EFN, Silva CA, Aikawa NE, Romiti R, Heise CO, Bonfa E, Pasoto SG. Thalidomide and Lenalidomide for Refractory Systemic/Cutaneous Lupus Erythematosus Treatment: A Narrative Review of Literature for Clinical Practice. J Clin Rheumatol 2021; 27:248-259. [PMID: 31693649 DOI: 10.1097/rhu.0000000000001160] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
BACKGROUND Thalidomide has shown exceptional results in systemic/cutaneous lupus erythematosus(SLE/CLE). Recently, lenalidomide has been also prescribed for SLE/CLE treatment. Literature regarding efficacy/adverse events for these drugs is scarce with a single systematic review and meta-analysis focused solely on thalidomide for refractory cutaneous lupus subtypes. OBJECTIVE We, therefore, addressed in this narrative review the efficacy/adverse effects of thalidomide and lenalidomide for SLE and CLE. In addition, we provide a specialist approach for clinical practice based on the available evidence. RESULTS Efficacy of thalidomide for refractory cutaneous lupus treatment was demonstrated by several studies, mostly retrospective with small sample size(≤20). The frequency of peripheral polyneuropathy is controversial varying from 15-80% with no consistent data regarding cumulative dose and length of use. Drug withdrawn results in clinical partial/complete reversibility for most cases (70%). For lenalidomide, seven studies (small sample sizes) reported its efficacy for SLE/CLE with complete/partial response in all patients with a mean time to response of 3 months. Flare rate varied from 25-75% occurring 0.5-10 months after drug withdrawn. There were no reports of polyneuropathy/worsening of previous thalidomide-induced neuropathy, but most of them did not perform nerve conduction studies. Teratogenicity risk exist for both drugs and strict precautions are required. CONCLUSIONS Thalidomide is very efficacious as an induction therapy for patients with severe/refractory cutaneous lupus with high risk of scarring, but its longstanding use should be avoided due to neurotoxicity. Lenalidomide is a promising drug for skin lupus treatment, particularly regarding the apparent lower frequency of nerve side effects.
Collapse
Affiliation(s)
| | | | | | | | - Carlos Otto Heise
- Neurology Department, Hospital das Clinicas, Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), Sao Paulo, Brazil
| | | | | |
Collapse
|
2
|
Taniguchi T, Nakamura M, Tsutao K, Otogawa K, Ogino Y, Asahi T. Reformation of Thalidomide from Its Hydrolysis Compound via Intramolecular Dehydration. CHEM LETT 2021. [DOI: 10.1246/cl.210099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Takuya Taniguchi
- Center for Data Science, Waseda University, 1-6-1 Nishiwaseda, Shinjuku-ku, Tokyo 169-8050, Japan
| | - Miri Nakamura
- Department of Life Science and Medical Bioscience, Graduate School of Advanced Science and Engineering, Waseda University, 2-2 Wakamatsu-cho, Shinjuku-ku, Tokyo 162-8480, Japan
| | - Koichi Tsutao
- Department of Life Science and Medical Bioscience, Graduate School of Advanced Science and Engineering, Waseda University, 2-2 Wakamatsu-cho, Shinjuku-ku, Tokyo 162-8480, Japan
| | - Kohei Otogawa
- Department of Life Science and Medical Bioscience, Graduate School of Advanced Science and Engineering, Waseda University, 2-2 Wakamatsu-cho, Shinjuku-ku, Tokyo 162-8480, Japan
| | - Yoshiyuki Ogino
- Department of Life Science and Medical Bioscience, Graduate School of Advanced Science and Engineering, Waseda University, 2-2 Wakamatsu-cho, Shinjuku-ku, Tokyo 162-8480, Japan
| | - Toru Asahi
- Department of Life Science and Medical Bioscience, Graduate School of Advanced Science and Engineering, Waseda University, 2-2 Wakamatsu-cho, Shinjuku-ku, Tokyo 162-8480, Japan
- Research Organization for Nano & Life Innovation, Waseda University, 513 Waseda-tsurumaki-cho, Shinjuku-ku, Tokyo 162-0041, Japan
| |
Collapse
|
3
|
Lan Q, Zhou Y, Wang X, Wang Y, Zhao C. Synthesis and biological evaluation of camptothecin substituted norcantharimide derivatives. Nat Prod Res 2020; 35:5752-5756. [PMID: 33078626 DOI: 10.1080/14786419.2020.1834546] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
In this paper, a series of novel derivatives of camptothecin substituted norcantharimide was designed by mimic strategy. These compounds were synthesized in moderate yields by directly coupling CPT with N-amino acid norcantharimides. Their cytotoxicity to four human tumour cell lines (HepG2, BGC-803, SW480 and PANC-1) and normal human cell lines L-O2 and HIEC was evaluated. The synthesized CPT substituted norcantharimide analogs (3g and 3f) showed better anti-hepatocarcinoma activity than CPT. Compounds 3d, 3e, 3g, 3h and 3i also showed strong inhibition activity against BGC803.
Collapse
Affiliation(s)
- Qing Lan
- Department of Medicinal Chemistry, Zunyi Medical University, Zunyi City, China
| | - Yiqi Zhou
- Department of Medicinal Chemistry, Zunyi Medical University, Zunyi City, China
| | - Xianheng Wang
- Department of Medicinal Chemistry, Zunyi Medical University, Zunyi City, China
| | - Yuhe Wang
- Department of Pharmacy, Zunyi Medical University Affiliated Hospital, Zunyi City, China
| | - Changkuo Zhao
- Department of Medicinal Chemistry, Zunyi Medical University, Zunyi City, China
| |
Collapse
|
4
|
Heim C, Pliatsika D, Mousavizadeh F, Bär K, Hernandez Alvarez B, Giannis A, Hartmann MD. De-Novo Design of Cereblon (CRBN) Effectors Guided by Natural Hydrolysis Products of Thalidomide Derivatives. J Med Chem 2019; 62:6615-6629. [PMID: 31251063 PMCID: PMC6750895 DOI: 10.1021/acs.jmedchem.9b00454] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2019] [Indexed: 12/16/2022]
Abstract
Targeted protein degradation via cereblon (CRBN), a substrate receptor of an E3 ubiquitin ligase complex, is an increasingly important strategy in various clinical settings, in which the substrate specificity of CRBN is altered via the binding of small-molecule effectors. To date, such effectors are derived from thalidomide and confer a broad substrate spectrum that is far from being fully characterized. Here, we employed a rational and modular approach to design novel and minimalistic CRBN effectors. In this approach, we took advantage of the binding modes of hydrolyzed metabolites of several thalidomide-derived effectors, which we elucidated via crystallography. These yielded key insights for the optimization of the minimal core binding moiety and its linkage to a chemical moiety that imparts substrate specificity. Based on this scaffold, we present a first active de-novo CRBN effector that is able to degrade the neo-substrate IKZF3 in the cell culture.
Collapse
Affiliation(s)
- Christopher Heim
- Department
of Protein Evolution, Max Planck Institute
for Developmental Biology, Max-Planck-Ring 5, 72076 Tübingen, Germany
| | - Dimanthi Pliatsika
- Faculty
for Chemistry und Mineralogy, Institute of Organic Chemistry, University of Leipzig, Johannisallee 29, 04103 Leipzig, Germany
| | - Farnoush Mousavizadeh
- Faculty
for Chemistry und Mineralogy, Institute of Organic Chemistry, University of Leipzig, Johannisallee 29, 04103 Leipzig, Germany
| | - Kerstin Bär
- Department
of Protein Evolution, Max Planck Institute
for Developmental Biology, Max-Planck-Ring 5, 72076 Tübingen, Germany
| | - Birte Hernandez Alvarez
- Department
of Protein Evolution, Max Planck Institute
for Developmental Biology, Max-Planck-Ring 5, 72076 Tübingen, Germany
| | - Athanassios Giannis
- Faculty
for Chemistry und Mineralogy, Institute of Organic Chemistry, University of Leipzig, Johannisallee 29, 04103 Leipzig, Germany
| | - Marcus D. Hartmann
- Department
of Protein Evolution, Max Planck Institute
for Developmental Biology, Max-Planck-Ring 5, 72076 Tübingen, Germany
| |
Collapse
|
5
|
Ogino Y, Tanaka M, Shimozawa T, Asahi T. LC-MS/MS and chiroptical spectroscopic analyses of multidimensional metabolic systems of chiral thalidomide and its derivatives. Chirality 2017; 29:282-293. [DOI: 10.1002/chir.22683] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2016] [Revised: 12/12/2016] [Accepted: 01/04/2017] [Indexed: 02/02/2023]
Affiliation(s)
- Yoshiyuki Ogino
- Waseda University; Department of Life Science and Medical Bioscience; Tokyo Japan
| | - Masahito Tanaka
- National Institute of Advanced Industrial Science and Technology (AIST); Research Institute of Instrumentation Frontier; Tsukuba Japan
| | - Togo Shimozawa
- Waseda University; Department of Life Science and Medical Bioscience; Tokyo Japan
| | - Toru Asahi
- Waseda University; Department of Life Science and Medical Bioscience; Tokyo Japan
| |
Collapse
|
6
|
Model of complex chiral drug metabolic systems and numerical simulation of the remaining chirality toward analysis of dynamical pharmacological activity. J Theor Biol 2015; 373:117-31. [PMID: 25791284 DOI: 10.1016/j.jtbi.2015.03.011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2014] [Revised: 03/06/2015] [Accepted: 03/07/2015] [Indexed: 11/22/2022]
Abstract
In this study, systems of complicated pathways involved in chiral drug metabolism were investigated. The development of chiral drugs resulted in significant improvement in the remedies available for the treatment of various severe sicknesses. Enantiopure drugs undergo various biological transformations that involve chiral inversion and thus result in the generation of multiple enantiomeric metabolites. Identification of the specific active substances determining a given drug׳s efficacy among such a mixture of different metabolites remains a challenge. To comprehend this complexity, we constructed a mathematical model representing the complicated metabolic pathways simultaneously involving chiral inversion. Moreover, this model is applied to the metabolism of thalidomide, which has recently been revived as a potentially effective prescription drug for a number of intractable diseases. The numerical simulation results indicate that retained chirality in the metabolites reflects the original chirality of the unmetabolized drug, and a higher level of enantiomeric purity is preserved during spontaneous degradation. In addition, chirality remaining after equilibration is directly related to the rate constant not only for chiral inversion but also for generation and degradation. Furthermore, the retention of chirality is quantitatively predictable using this combination of kinetic parameters. Our simulation results well explain the behavior of thalidomide in the practical biological experimental data. Therefore, this model promises a comprehensive understanding of dynamic metabolic systems involving chiral drugs that express multiple enantiospecific drug efficacies.
Collapse
|
7
|
Otogawa K, Ishikawa K, Shiro M, Asahi T. Crystal structure of (S)-4-carbamoyl-4-(1,3-dioxo-isoindolin-2-yl)butanoic acid. ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS 2015; 71:107-9. [PMID: 25705465 PMCID: PMC4331919 DOI: 10.1107/s2056989014027121] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/29/2014] [Accepted: 12/11/2014] [Indexed: 11/10/2022]
Abstract
The title compound is a one of the first-step hydrolysis products of thalidomide. In the crystal, each molecule is linked via six neighbouring molecules into a three-dimensional network through N—H⋯O and O—H⋯O hydrogen bonds. In the title compound, C13H12N2O5, the phthalimide ring system is essentially planar, with a maximum deviation of 0.0479 (14) Å. In the crystal, each molecule is linked via six neighbouring molecules into a three-dimensional network through N—H⋯O and O—H⋯O hydrogen bonds, which form an R32(8) ring motif.
Collapse
Affiliation(s)
- Kohei Otogawa
- Graduate school of Advanced Science and Engineering, Waseda University (TWIns), Tokyo 162-8480, Japan
| | - Kazuhiko Ishikawa
- Graduate school of Advanced Science and Engineering, Waseda University (TWIns), Tokyo 162-8480, Japan
| | - Motoo Shiro
- Consolidated Research Institute for Advanced Science and Medical Care, Waseda University (ASMeW), Tokyo 162-0041, Japan
| | - Toru Asahi
- Graduate school of Advanced Science and Engineering, Waseda University (TWIns), Tokyo 162-8480, Japan ; Consolidated Research Institute for Advanced Science and Medical Care, Waseda University (ASMeW), Tokyo 162-0041, Japan
| |
Collapse
|
8
|
PI3K/Akt signaling pathway is required for neuroprotection of thalidomide on hypoxic–ischemic cortical neurons in vitro. Brain Res 2010; 1357:157-65. [DOI: 10.1016/j.brainres.2010.08.007] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2010] [Revised: 07/31/2010] [Accepted: 08/04/2010] [Indexed: 01/06/2023]
|
9
|
Srivastava RM, Neves Filho RAW, da Silva CA, Bortoluzzi AJ. First ultrasound-mediated one-pot synthesis of N-substituted amides. ULTRASONICS SONOCHEMISTRY 2009; 16:737-42. [PMID: 19435673 DOI: 10.1016/j.ultsonch.2009.04.006] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/17/2008] [Revised: 03/17/2009] [Accepted: 04/15/2009] [Indexed: 05/17/2023]
Abstract
Ultrasound irradiation, an efficient and innocuous technique of reagent activation for synthesizing organic compounds, has been applied with success to transform seven carboxylic acids to fourteen secondary amides in good to excellent yields. The reaction has worked well either with aryl or alkyl carboxylic acids as well as with aromatic or aliphatic amines. This methodology is expeditious and reliable for preparing secondary carboxamides which in many cases are embedded in the C-5 side-chain of 1,2,4-oxadiazoles (14, 15, 17-27). The elemental analyses of new compounds (19-27) in conjunction with the spectral data of all synthesized amides gave an idea about their structures, while the crystallographic data of one of the compounds (26) supplied information concerning the configurational behavior of the amidic part and also the conformational aspect of the entire molecule in the crystalline state.
Collapse
Affiliation(s)
- Rajendra M Srivastava
- Departamento de Quimica Fundamental, Universidade Federal de Pernambuco, 50.740-540 Recife, PE, Brazil.
| | | | | | | |
Collapse
|
10
|
Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proc Natl Acad Sci U S A 2009; 106:8573-8. [PMID: 19433787 DOI: 10.1073/pnas.0901505106] [Citation(s) in RCA: 167] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Thalidomide is a potent teratogen that induces a range of birth defects, most commonly of the developing limbs. The mechanisms underpinning the teratogenic effects of thalidomide are unclear. Here we demonstrate that loss of immature blood vessels is the primary cause of thalidomide-induced teratogenesis and provide an explanation for its action at the cell biological level. Antiangiogenic but not antiinflammatory metabolites/analogues of thalidomide induce chick limb defects. Both in vitro and in vivo, outgrowth and remodeling of more mature blood vessels is blocked temporarily, whereas newly formed, rapidly developing, angiogenic vessels are lost. Such vessel loss occurs upstream of changes in limb morphogenesis and gene expression and, depending on the timing of drug application, results in either embryonic death or developmental defects. These results explain both the timing and relative tissue specificity of thalidomide embryopathy and have significant implications for its use as a therapeutic agent.
Collapse
|
11
|
Hashimoto Y. Thalidomide as a Multi-Template for Development of Biologically Active Compounds. Arch Pharm (Weinheim) 2008; 341:536-47. [DOI: 10.1002/ardp.200700217] [Citation(s) in RCA: 66] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
12
|
Progesterone receptor antagonists with a 3-phenylquinazoline-2,4-dione/2-phenylisoquinoline-1,3-dione skeleton. Bioorg Med Chem 2008; 16:7046-54. [DOI: 10.1016/j.bmc.2008.05.016] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2008] [Revised: 04/21/2008] [Accepted: 05/05/2008] [Indexed: 11/23/2022]
|